Misplaced Pages

Revision as of 03:25, 18 October 2017

Ideal sources for Misplaced Pages's health content are defined in the guideline Misplaced Pages:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Beta blocker. PubMed provides review articles from the past five years (limit to free review articles) The TRIP database provides clinical publications about evidence-based medicine. Other potential sources include: Centre for Reviews and Dissemination and CDC

This is the talk page for discussing improvements to the Beta blocker article. This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic. New to Misplaced Pages? Welcome! Learn to edit; get help. Assume good faith Be polite and avoid personal attacks Be welcoming to newcomers Seek dispute resolution if needed Article policies Neutral point of view No original research Verifiability

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL

Archives: 1Auto-archiving period: 2 months

Pharmacology C‑class Top‑importance

This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Misplaced Pages. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology C This article has been rated as C-class on Misplaced Pages's content assessment scale. Top This article has been rated as Top-importance on the project's importance scale.

Unsourced

Moved here per WP:PRESERVE as this is almost all unsourced. Per WP:BURDEN please do not restore without finding reliable sources, checking the content against them, and citing the sources.

Examples

Nonselective agents

• Propranolol
• Bucindolol (has additional α1-blocking activity)
• Carteolol
• Carvedilol (has additional α1-blocking activity)
• Labetalol (has additional α1-blocking activity)
• Nadolol
• Oxprenolol (has intrinsic sympathomimetic activity)
• Penbutolol (has intrinsic sympathomimetic activity)
• Pindolol (has intrinsic sympathomimetic activity)
• Sotalol (not considered a "typical beta-blocker")
• Timolol

β₁-selective agents

Also known as cardioselective

• Acebutolol (has intrinsic sympathomimetic activity, ISA)
• Atenolol
• Betaxolol
• Bisoprolol
• Celiprolol (has intrinsic sympathomimetic activity)
• Metoprolol
• Nebivolol

β₂-selective agents

• Butaxamine
• ICI-118,551

β₃-selective agents

• SR 59230A

Comparative information

Pharmacological differences

• Agents with intrinsic sympathomimetic action (ISA)
  • Acebutolol, pindolol, labetalol, mepindolol, oxprenolol, celiprolol
• Agents organized by lipid solubility (lipophilicity)
  • High lipophilicity: propranolol, labetalol
  • Intermediate lipophilicity: metoprolol, bisoprolol, carvedilol, acebutolol, timolol, pindolol
  • Low lipophilicity (also known as hydrophilic beta-blockers): atenolol, nadolol, and sotalol
• Agents with membrane stabilizing effect
  • Acebutolol, propranolol

Indication differences

• Agents specifically labeled for cardiac arrhythmia
  • Esmolol, sotalol, landiolol
• Agents specifically labeled for congestive heart failure
  • carvedilol, sustained-release metoprolol, bisoprolol,
• Agents specifically labeled for glaucoma
  • Betaxolol, carteolol, levobunolol, metipranolol, timolol
• Agents specifically labeled for myocardial infarction
  • Atenolol, metoprolol, propranolol
• Agents specifically labeled for migraine prophylaxis
  • Timolol, propranolol

Propranolol is the only agent indicated for control of tremor, portal hypertension, and esophageal variceal bleeding, and used in conjunction with α-blocker therapy in phaeochromocytoma.

References

1. ^ "Comparison of Oral Beta-Blockers". pharmacist.therapeuticresearch.com. Therapeutic Research Center. Retrieved 30 April 2017.
2. Rosendorff C (1993). "Beta-blocking agents with vasodilator activity". Journal of Hypertension. Supplement. 11 (4): S37–40. doi:10.1097/00004872-199306003-00009. PMID 8104240.
3. "CARTEOLOL". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 18 October 2017.
4. ^ "oxprenolol". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 18 October 2017.
5. ^ "Celiprolol". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 18 October 2017.
6. "Butaxamine". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 18 October 2017.
7. "ICI 118551 hydrochloride". abcam.com. Abcam plc. Retrieved 18 October 2017.
8. "SR 59230A". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 18 October 2017.
9. ^ Larochelle, Pierre; Tobe, Sheldon W.; Lacourcière, Yves (May 2014). "β-Blockers in Hypertension: Studies and Meta-analyses Over the Years". Canadian Journal of Cardiology. 30 (5): S16–S22. doi:10.1016/j.cjca.2014.02.012. {{cite journal}}: |access-date= requires |url= (help); no-break space character in |title= at position 59 (help)
10. Mulrow, edited by Detlev Ganten, Patrick J. (1990). Pharmacology of Antihypertensive Therapeutics. Berlin, Heidelberg: Springer Berlin Heidelberg. p. 523. ISBN 9783642742095. {{cite book}}: |access-date= requires |url= (help); |first1= has generic name (help)CS1 maint: multiple names: authors list (link)
11. Zipursky, Jonathan S.; Macdonald, Erin M.; Luo, Jin; Gomes, Tara; Mamdani, Muhammad M.; Paterson, J. Michael; Juurlink, David N. (June 2017). "Lipophilic β-Blockers and Suicide in the Elderly". Journal of Clinical Psychopharmacology. 37 (3): 381–384. doi:10.1097/JCP.0000000000000695. Retrieved 18 October 2017.
12. "Drugs to Prevent Migraine in Adults". pharmacist.therapeuticresearch.com. Therapeutic Research Center. Retrieved 30 April 2017.
13. Cite error: The named reference Rossi was invoked but never defined (see the help page).

• C-Class pharmacology articles
• Top-importance pharmacology articles
• WikiProject Pharmacology articles